Physician profile
Michael D Nagata
NPI 1124054184
$1,705.38
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $170 · 2021: $136 · 2022: $422 · 2023: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $333.83 | 2019-2023 | Evenity, Prolia |
| Novo Nordisk INC | $327.73 | 2020-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $198.92 | 2019-2023 | Mounjaro |
| Pfizer INC. | $131.38 | 2020-2023 | |
| Glaxosmithkline, LLC. | $78.88 | 2022-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $59.14 | 2019-2023 | Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $56.25 | 2022 | |
| Idorsia Pharmaceuticals US INC | $55.59 | 2022-2023 | Quviviq |
| Eisai INC. | $52.31 | 2021-2022 | |
| Boston Scientific Corporation | $50.01 | 2023 | Wavewriter Alpha Prime 16 |
| Almatica Pharma LLC | $48.98 | 2023 | Loreev Xr, Gralise |
| Vanda Pharmaceuticals INC. | $32.38 | 2019 | |
| Phadia US INC. | $32.06 | 2023 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $25.64 | 2020 | |
| Astellas Pharma US INC | $23.78 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $23.44 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.73 | 2023 | Tradjenta, Jardiance, Synjardy |
| Exact Sciences Corporation | $21.92 | 2023 | Cologuard Collection Kit |
| Impel Pharmaceuticals INC. | $20.41 | 2022 | |
| Genentech USA, INC. | $19.71 | 2020 | |
| Ibsa Pharma INC. | $19.43 | 2022 | |
| Amag Pharmaceuticals, INC. | $19.07 | 2019 | |
| Janssen Scientific Affairs, LLC | $18.04 | 2020 | |
| Cranial Technologies, INC | $18.03 | 2023 | Doc Band |
| Kowa Pharmaceuticals America, INC. | $15.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nagata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.